Figure (Lucentis 01)
Lucentis Injection, Solution
Product Images NDC 50242-080
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Lucentis (NDC 50242-080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Lucentis 02)
Figure (Lucentis 03)
Figure (Lucentis 04)
Figure 1 (Lucentis 05)
The text describes a syringe cap with a rubber stopper and finger grip, along with a Luerlock 0.05 mL dose mark plunger rod. The accompanying figure shows what the items look like.*
Figure 2 (Lucentis 06)
Figure 3 (Lucentis 07)
Figure 4 (Lucentis 08)
Figure 5 (Lucentis 09)
Figure (Lucentis 10)
Figure (Lucentis 11)
Figure (Lucentis 12)
Figure (Lucentis 13)
Figure (Lucentis 14)
This text refers to a small syringe with a volume capacity of 0.05 milliliters.*
Figure 1 (Lucentis 15)
Mean Change in Visual Activity for a condition or study named AMD-1 is being measured in meters or getters.*
Figure 2 (Lucentis 16)
Figure 3 (Lucentis 17)
Figure 4 (Lucentis 18)
Figure 5 (Lucentis 19)
Figure 6 (Lucentis 20)
Figure 7 (Lucentis 21)
Figure 8 (Lucentis 22)
Figure 9 (Lucentis 23)
Principal Display Panel (0.5 mg Syringe Label)
This is a description of a drug product called Lucentis. It is a sterile, single-use syringe used for intravitreal injection only. The drug is indicated for the treatment of wet age-related macular degeneration (WAMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). The syringe contains 0.5mg of ranibizumab. It is important to keep the product refrigerated and protected from light. It is manufactured by Genentech and is identified by the NDC code 50242.080-03.*
Principal Display Panel (0.3 mg Syringe Packet)
This is a description of a medication called Lucentis (ranibizumab injection) that comes in a pre-filled syringe with a 0.3 mg dose. It is used for intravitreal injection only and is indicated for treating diabetic macular edema (DME) and diabetic retinopathy (DR). The medication is sterile, for single use only and should be kept refrigerated, protected from light, and not frozen. The text also includes the National Drug Code (NDC) number and an identification number (10198958).*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
